NEW YORK (360Dx) – Precipio said this week that its preliminary first quarter revenues rose 286 percent year over year to $712,000. The increase was driven by a restructured and expanded sales staff; a separate, dedicated sales staff for pathology services and Ice Cold PCR/Pharma projects; and the increased cross-selling of pathology services with the ICP lung cancer treatment resistance panel, the firm said.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.